Influence of APOE gene polymorphisms on interferon-beta treatment response in multiple sclerosis;Influencia del polimorfismo del gen de la APOE en la respuesta al tratamiento con interferón beta en esclerosis múltiple

Neurologia

Volumn 26, Issue 3, 2011, Pages 137-142

  Guerrero, A L ^a   Tejero, M A ^a   Gutierrez F ^a   Martin Polo J ^a   Iglesias, F ^a   Laherran, E ^a   Martin Serradilla J I ^a   Merino, S ^a  

^a Gerencia Regional de Salud de Castilla y León   (Spain)

Author keywords

APOE; Multiple sclerosis; Pharmacogenetics; Treatment response

Indexed keywords

APOLIPOPROTEIN E; BETA INTERFERON; BETA1A INTERFERON; CHOLINESTERASE INHIBITOR; INTERFERON BETA SERINE; INTERLEUKIN 10;

ALLELE; ALZHEIMER DISEASE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DISEASE DURATION; DNA POLYMORPHISM; FEMALE; HETEROZYGOSITY; HUMAN; HYPERCHOLESTEROLEMIA; INFORMATION PROCESSING; MALE; MULTIPLE SCLEROSIS; ONSET AGE; POLYMERASE CHAIN REACTION; RELAPSE; RETROSPECTIVE STUDY;

ADJUVANTS, IMMUNOLOGIC; ADULT; APOLIPOPROTEINS E; FEMALE; HUMANS; INTERFERON-BETA; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79952739574     PISSN: 02134853     EISSN: 15781968     Source Type: Journal    
DOI: 10.1016/j.nrl.2010.06.003     Document Type: Article

References (36)

1. Fernández Fernández O., Fernández Sánchez V.E., Mayorga C., Guerrero Fernández M., León A., Tamayo Toledo J.A., et al. Respuesta al interferón beta en la esclerosis múltiple asociada con la discapacidad previa al tratamiento. Rev Neurol. 2006, 43:322-329.
2. Tomassini V., Paolillo A., Russo P., Giugni E., Prosperini L., Gasperini C., et al. Predictors of long-term clinical response to interferon beta therapy in relapsing multiple sclerosis. J Neurol. 2006, 253:287-293.
3. Caon C. Maximising therapeutic outcomes in patients failing on current therapy. J Neurol Sci. 2009, 277:533-536.
4. Río J., Nos C., Tintoré M., Téllez N., Galán I., Pelayo R., et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis Patients. Ann Neurol. 2006, 59:344-352.
5. Rudick R.A., Lee J.-C., Simon J., Ransohoff R.M., Fisher E. Defining interferon beta response status in multiple sclerosis patients. Ann Neurol. 2004, 56:548-555.
6. Stürzebecher S., Wandinger K.P., Rosenwald A., Sathyamoorthy M., Tzou A., Mattar P., et al. Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain. 2003, 126:1419-1429.
7. Burwick R.M., Ramsay P.P., Haines Jl, Hauser Sl, Oksenberg J.R., Pericak-Vance M.A., et al. APOE epsilon variation in multiple sclerosis susceptibility and disease severity. Some answers. Neurology. 2006, 66:1373-1383.
8. Pedro-Botet J., Schaefer E.J., Bakker-Arkema R.G., Black D.M., Stein E.M., Corella D., et al. Apolipoprotein E genotype affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis. 2001, 158:183-193.
9. Pozzilli C., Prosperini L. Clinical markers of therapeutic response to disease modifying drugs. Neurol Sci. 2008, 29:S211-S213.
10. Cohen B.A., Khan O., Jeffery D.R., Bashir K., Rizvi S.A., Fox E.J., et al. Identifying and treating patients with suboptimal responses. Neurology. 2004, 63(Suppl 6):S33-S40.
11. Villoslada P., Oksenberg J.R., Río J., Montalbán X. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2004, 62:1653.
12. Waubant E., Vukusic S., Gignoux L., Durand-Dubief F., Achiti I., Blanc S., et al. Clinical characteristics of responders to interferon therapy for relapsing MS. Neurology. 2003, 61:184-189.
13. Leyva L., Fernández O., Fedetz M., Blanco E., Fernández V.E., Oliver B., et al. IFNAR 1 and IFNAR2 polymorphisms confer susceptibility to multiple sclerosis but not to interferon-beta treatment response. J Neuroimmunol. 2005, 163:165-171.
14. Cohen J.A., Carter Jl, Kinkel R.P., Schwid S.R. Therapy of relapsing multiple sclerosis. Treatment approaches for nonresponders. J Neuroimmunol. 1999, 98:29-36.
15. Río J., Nos C., Tintoré M., Borrás C., Galán I., Comabella M., et al. Assessment of different treatment failure criteria in a cohort of relapsing-remitting multiple sclerosis Patients treated with interferon beta: implications for clinical trials. Ann Neurol. 2002, 52:400-406.
16. Rudick R.A. Measuring the impact of therapeutic intervention. Thinking beyond traditional outcomes. Neurology. 2010, 74(Suppl 3):S1-S2.
17. Cutter G. Evidence of treatment benefit: is seeing believing or obfuscation by statistics. Mult Scler. 2009, 15:1251-1252.
18. Comabella M., Craig D.W., Morcillo-Suárez C., Río J., Navarro A., Fernández M., et al. Genome-wide Scan of 500,000 Single-Nucleotide Polymorphisms Among Responders and Nonresponders to Interferon Beta Therapy in Multiple Sclerosis. Arch Neurol. 2009, 66:972-978.
19. Chiu A.W., Richert N., Ehrmantraut M., Ohayon J., Gupta S., Bomboi G., et al. Heterogeneity in response to Interferon Beta in patients with Multiple Sclerosis. A 3-year monthly imaging study. Arch Neurol. 2009, 66:39-43.
20. Martínez A., De las Heras V., Mas Fontao A., Bartolomé M., De la Concha E.G., Urcelay E., et al. An IFNG polymorphism is associated with interferon-beta response in spanish MS Patients. J Neuroimmunol. 2006, 173:196-199.
21. Gilli F., Marnetto F., Caldano M., Sala A., Malucchi S., Capobianco M., et al. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler. 2006, 12:47-57.
22. Laske C., Oschmann P., Tofighi J., Kühne B.S., Diehl H., Brezenger T., et al. Prognostic value of soluble tumor necrosis factor receptors 1 and 2 in multiple sclerosis patients treated with interferon beta 1b. Eur Neurol. 2001, 46:210-214.
23. Wandinger K.-P., Lünemann J.D., Wengert O., Bellmann-Strobl J., Aktas O., Weber A., et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet. 2003, 361:2036-2043.
24. Walsh E.C., Guschwan-Mcmahon S., Daly M.J., Hafler D.A., Rioux J.D. Genetic analysis of multiple sclerosis. J Autoimmunity. 2003, 21:111-116.
25. Wergeland S., Beiske A., Nyland H., Hovdal H., Jensen D., Larsen J.P., et al. IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. Eur J Neurol. 2005, 12:171-175.
26. Villoslada P., Barcellos L.F., Río J., Begovich A.B., Tintore M., Sastre-Garriga J., et al. The HLA locus and multiple sclerosis in Spain. Role in disease susceptibility, clinical course and response to interferon-beta. J Neuroimmunol. 2002, 130:194-201.
27. Sriram U., Barcellos L.F., Villoslada P., Río J., Baranzini S.E., Caillier S., et al. Pharmacogenomic analysis of interferon receptor polymorphisms in multiple sclerosis. Genes and Immunity. 2003, 4:147-152.
28. Fernández O., Fernández V., Mayorga C., Guerrero M., León A., Tamayo J.A., et al. HLA class II and response to interferon-beta in multiple sclerosis. Acta Neurol Scand. 2005, 112:391-394.
29. Cenit M.D.C., Blanco-Kelly F., De las Heras V., Bartolomé M., De la Concha E.G., Urcelay E., et al. Glypican 5 is an interferon-beta response gene: a replication study. Mult Scler. 2009, 15:913-917.
30. Corona T., Guerrero-Camacho J.L., Alonso-Vilatela M.E., Flores-Rivera J.J. Ausencia de relación entre los genotipos de apolipoproteína E y la gravedad de la esclerosis múltiple en pacientes mexicanos. Rev Neurol. 2010, 50:19-22.
31. Portaccio E., Zipoli V., Goretti B., Hakiki B., Nacmias B., Siracusa G., et al. Apolipoprotein E epsilon 4 allele is not associated with disease course and severity in multiple sclerosis. Acta Neurol Scand. 2009, 120:439-441.
32. Van der Walt A., Stankovich J., Bahlo M., Taylor B.V., Van der Mei I.A.F., Foote S.J., et al. Apolipoprotein genotype does not influence MS severity, cognition, or brain atrophy. Neurology. 2009, 73:1018-1025.
33. Guerrero A.L., Laherrán E., Gutiérrez F., Martín-Polo J., Alcázar C., Peralta J., et al. Apolipoprotein E genotype does not associate with disease severity measured by Multiple Sclerosis Severity Score. Acta Neurol Scand. 2008, 117:21-25.
34. Roxburgh R.H., Seaman S.R., Masterman T., Hensiek A.E., Sawcer S.J., Vukusic S., et al. Multiple Sclerosis Severity Score. Neurology. 2005, 64:1144-1151.
35. Neuhaus O., Stüve O., Zamvil S.S., Hartung H.-P. Are statins a treatment option for multiple sclerosis?. Lancet Neurol. 2004, 3:369-371.
36. Paul F., Waiczies S., Wuerfel J., Bellmann-Strobl J., Dörr J., Waiczies H., et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS ONE. 2008, 3:e1928.